Title |
Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report
|
---|---|
Published in |
BMC Dermatology, September 2014
|
DOI | 10.1186/1471-5945-14-15 |
Pubmed ID | |
Authors |
Sara Falivene, Francesca Maria Giugliano, Antonio Maria Grimaldi, Rossella Di Franco, Diego Toledo, Matteo Muto, Fabrizio Cammarota, Valentina Borzillo, Paolo Antonio Ascierto, Paolo Muto |
Abstract |
Cutaneous squamous cell carcinoma (SCC) is the second most frequency of all skin tumors. Incidence of SCC has risen significantly due to an increased sun exposure and the number of immunodeficient patients. Cutaneous SCC is characterized by high Epidermal growth factor receptor (EGFR) expression with low frequency of RAS mutations. Generally, locoregional surgery is curative and systemic therapy is not indicated. We evaluated the activity and toxicity profile of tomotherapy concomitant with Cetuximab, followed by Cetuximab as single agent therapy in a patient affected by unresectable, locally advanced cutaneous SCC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 3% |
Netherlands | 1 | 3% |
Unknown | 28 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 20% |
Student > Ph. D. Student | 5 | 17% |
Student > Doctoral Student | 3 | 10% |
Researcher | 3 | 10% |
Student > Postgraduate | 2 | 7% |
Other | 3 | 10% |
Unknown | 8 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 40% |
Nursing and Health Professions | 5 | 17% |
Biochemistry, Genetics and Molecular Biology | 2 | 7% |
Sports and Recreations | 1 | 3% |
Unspecified | 1 | 3% |
Other | 0 | 0% |
Unknown | 9 | 30% |